NodThera Picks Genzyme Exec Adam Keeney for President and CEO Role

Adam Keeney has joined NodThera as president and CEO. He is also joining the company’s board of directors. Alan Watt, who had been serving as interim CEO, will resume his role as chief scientific officer of the Cambridge, UK, company. With Keeney’s appointment, NodThera will also open a new office in the Boston area.

Keeney comes to NodThera from Sanofi (NYSE: [[ticker:SNY]]) subsidiary Genzyme, where he was global head of Sanofi Genzyme business development. Before Genzyme, Keeney held several roles at Johnson & Johnson (NYSE: [[ticker:JNJ]]). NodThera, which is developing treatments for diseases characterized by chronic inflammation, raised $40 million in a Series A round of financing in June.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan